Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergopharma GmbH & Co. KG
• Treatments: Histamine; Histamine phosphate; Immunologic Factors

Criteria

Inclusion Criteria:

• main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens

• positive SPT

• positive EAST

• positive specific provocation test

Exclusion Criteria:

• serious chronic diseases

• other perennial allergies